During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma.
Targeted Oncology: What therapeutic options would you consider at this point?
BREM: [Based on the NCCN (National Comprehensive Cancer Network) guidelines,] up-front chemotherapy with CHOP is an option.1 We will not have the CHOP vs EPOCH [etoposide (Toposar), prednisone, vincristine, cyclophosphamide, doxorubicin] discussion now. Unfortunately, when a patient progresses after that, youre going to restage them and think about options such as chimeric antigen receptor [CAR] T-cell therapy. Now, with some of the newer agents being approved, the toxicity profile is getting a bit better, so the pool of [patients] who are eligible for CAR T-cell therapy is probably increasing. Furthermore, youre going to think about a clinical trial if you had one available. If a patient only had 1 site of disease, you could think about palliative radiation, although in my experience youre not going to reach for it often.
The question about whether you should consider transplant after some sort of salvage therapy with one of these novel therapies is very much up in the air. The revised NCCN guidelines [for treatment of patients with DLBCL] came out recently and I feel things have changed since they got published. The preferred regimens that are FDA approved are gemcitabine [Gemzar], oxaliplatin [Eloxatin] plus rituximab [R-GemOx] or polatuzumab [Polivy] plus or minus bendamustine [Treanda] plus or minus rituximab [polaBR]. Ive never used CEPP [cyclophosphamide, etoposide, prednisone, procarbazine (Matulane)], CEOP [cyclophosphamide, etoposide, vincristine, prednisone], or EPOCH in this situation. GDP [gemcitabine, dexamethasone, cisplatin], [is a treatment that] Im not necessarily sure is that different from R-GemOx. Ive never given vinorelbine [Navelbine] and I would not give single-agent rituximab.
Now we have tafasitamab [Monjuvi] plus lenalidomide [Revlimid]tafasitamab being an anti-CD19 antibody, lenalidomide being the immunomodulatory drug that we know and love from multiple myeloma.
Others that are useful in certain circumstances are brentuximab vedotin [Adcetris] for CD30-positive disease. There are some more ongoing data in this situation; however, I dont use bendamustine plus rituximab much because it doesnt work for very long. Ibrutinib [Imbruvica] has activity of about 30% in nongerminal center B-cell [nGCB] DLBCL and in times of desperation I have reached for that. Lenalidomide plus rituximab was used for a fair amount before tafasitamab plus lenalidomide was approved and I feel were going to move away from that now.1
There are important footnotes in the NCCN guidelines. We have 3 anti-CD19 CAR T-cell therapies that are technically FDA approved only after 2 prior chemoimmunotherapy regimens, so thats something to keep in mind. This patient had both CHOP and R-ICE, so [she] would potentially be a candidate. Loncastuximab [Zynlonta] is a conjugated anti-CD19 that has a [tesirine] linked to it and is approved after 2 or more lines of systemic therapy.
Whats not clear is this idea of bridging people to CAR T-cell therapy when a patient has a lot of symptoms and you want to get them feeling better but you know that CAR T-cell therapy is going to take time. Its going to take time to [do leukapheresis] on them, send it off to get made, and then time to get a response. Sometimes you do something else while you get that going. Some of these other drugs we mentioned target CD19, so should you be doing 2 drugs that target CD19? The jury is very much still out on that.
Please discuss the poll results.
Were not supposed to compare single-arm phase 2 studies, but we dont have any randomized studies comparing CAR T-cell therapies. The ZUMA-1 study [NCT02348216] used axicabtagene ciloleucel [axi-cel; Yescarta],. Overall response rate [ORR] was 83%, CR [complete response] rate was 58%. Theres going to be a recurring theme in novel agents in DLBCL, which is that if you achieve a CR, you do better. There is a plateau, but some of these patients who achieved a CR might be cured, so it is important to look at the CR rate. Toxicity was about 11% for grade 3 and 4 cytokine release syndrome and about 32% for neurotoxicity.2,3
Maybe it is because it was the first construct, and we were still getting used to it and maybe thats why some of the other ones do better with neurotoxicity. The newest treatment, lisocabtagene maraleucel [liso-cel (Breyanzi)], is being pushed as the safer option and the evidence for that is based on the grade 3 and 4 neurotoxicity [of 11%], and the CR rate is still quite good at 53%.4
What are you most likely to recommend for this patient?
Polatuzumab vedotin is a monoclonal antibody targeting CD79b, which is one of the components of the B-cell receptor pathway. Its conjugated to a payload, in this case MMAE [monomethyl auristatin E], which is one of those conjugated antibodies where the idea is that you only deliver the payload to the malignant cell because thats whats expressing the marker. The payload inhibits tubulin polymerization, leading to growth arrest and apoptosis.5
We have phase 2 data looking at pola-BR. It was for patients who had biopsy-confirmed relapsed/refractory DLBCL after at least 1 prior line of therapy. For some of the patients, this was their second line of therapy. One of the toxicities of polatuzumab is peripheral neuropathy, so a patient couldnt have had greater than grade 1 neuropathy going into the study. These were patients who at the investigators discretion were felt to not be eligible for transplant or had previously failed transplant. The 80 patients who had DLBCL were randomized to BR vs pola-BR given once every 21 days for 6 cycles.6
The baseline characteristics of the study were a median age of late 60s or early 70s; a little bit unbalanced IPI [International Prognostic Index] risk score, with slightly higher IPIs in the BR arm; most patients had Ann Arbor stage III or IV disease; the median lines of therapy in both arms were 2; most patients had greater than 3 prior lines of therapy; most had less than 12 months of response to their last therapy; and most were considered refractory to the last therapy with only a small percentage who got stem cell transplant. Because some drugs work better in GCB DLBCL vs nonGCB DLBCL, this group of patients tended to be nonGCB DLBCL.6
The primary end point was CR rate assessed by PET scan. In the pola-BR arm by investigator response, the ORR, which was the CR plus the PR, was 45% and that was obviously significantly better than the BR alone arm, [which was 17.5%].6
There was an improvement in the median progression-free survival [mPFS] for the pola-BR vs BR arm both by IRC [independent review committee] and by investigator. [The mPFS by IRC was 9.5 months for pola-BR vs 3.7 months for BR (HR, 0.36; 95% CI, 0.21- 0.63; P < .001)].6
The overall survival [OS], which is not the primary end point but something we always think about in DLBCL because we want this to be a curable disease, had a plateau in its curve as you get out to 2-plus years, which can be encouraging. [The median OS was 12.4 months for pola-BR vs 4.7 months for BR (HR, 0.42; 95% CI, 0.24- 0.75; P = .002)].6
What is your reaction to the efficacy data for polatuzumab vedotin plus BR? Which data stand out to you?
Its worth keeping in mind that prior to the approval of polatuzumab in 2019, these patients had an mOS of 6 months. Its kind of amazing how far weve come and that we have options for this patient population.
Do you have data for just using polatuzumab vedotin with rituximab and without the bendamustine if you have unfit patients with an ECOG score of 2 to 3?
This is a debate that I have listened to people talk about, because obviously as youre pointing out, it was pola-BR vs BR but do you really need the B, and for that matter do you really need the R? There were some earlier phase 1 studies looking at just polatuzumab and I think just pola-R, and the response rates werent that much lower. There are some [patients] who, because the bendamustine can cause cytopenia, if you are going to eventually, for example, try to take a patient to a CAR T-cell therapy, you must be able to collect their cells. Because theres some concern that bendamustine might impair stem cell collection, there are [patients] who use polatuzumab either alone or just pola-R and skip the B. A couple of times when Ive been in the hospital, we had 1 or 2 [patients to whom] we gave single-agent polatuzumab. They had a response, improved symptom burden, and we were able to get them out of the hospital.
What toxicities should clinicians be aware of?
Anytime were talking about these therapies, we need to talk about their toxicity. Although BR is not the most effective drug in DLBCL, its well tolerated outside of the cytopenia. When you add in the polatuzumab, you do have more anemia, more thrombocytopenia, but not more febrile neutropenia. The amount of grade 3 and 4 anemia and neutropenia is not all that much worse than the BR alone. In terms of GI [gastrointestinal] disturbances, you see them on both sides, maybe slightly more low-grade diarrhea in the polatuzumab arm, but there is similar fatigue and decrease in appetite. Obviously, peripheral neuropathy, a toxicity associated with the payload, is higher in the pola-BR arm, but interestingly there was no grade 3 or 4 peripheral neuropathy. They were all low grade. Grade 3 and 4 infections were similar in both arms. Even though there is more cytopenia when you add the polatuzumab, you didnt have more infections or febrile neutropenia.
What other therapeutic options are available?
About 3 to 4 years ago we had nothing approved in this space and were making stuff up by giving more chemotherapy, giving ibrutinib [Imbruvica] off label, or giving rituximab plus lenalidomide. We then got pola-BR followed by tafasitamab plus lenalidomide. Tafasitamab is an anti- CD19 monoclonal antibody, and we combine it with lenalidomide, an immunomodulatory drug that has a lot of explanations on how it works in vivo, but its all very [uncertain]. Theoretically, it turns the [bone marrow] into an antitumor environment.
What data support the use of tafasitamab?
Phase 2 data from the single-arm L-MIND study [NCT02399085] are what we have, so well work with that. It is what led to the FDA approval of tafasitamab plus lenalidomide. This was a slightly different population of patients who had at least 1 but up to 3 prior regimens compared with the pola-BR data, where patients had more prior lines of therapy. Patients were those felt to not be eligible for transplant. Interestingly, primary refractory patients were explicitly excluded from this study. In the beginning, they defined this as patients who progressed within 3 months of therapy, but they ended up having a few patients who progressed within 6 months of therapy, which some people would consider primary refractory. Anyway, just worth noting that primary refractory patients were excluded from this study, as opposed to the pola-BR study where there were patients who had a less than 12-month response to prior therapy.7
Tafasitamab is a monoclonal antibody delivered intravenously [IV] and given more frequently in the beginning and then spread out. The lenalidomide dose was relatively high here at 25 mg, which is a bit different than what we do, for example, in follicular lymphoma. Patients who had stable disease went on tafasitamab maintenance. The patients got 1 year of the combination and then if they had stable disease or better, they got the tafasitamab as a maintenance. The primary end point was ORR, which is again different from pola-BR where the primary end point was CR.7
Can you discuss the relevant data regarding tafasitamab?
The primary end point was ORR. With a median follow-up of 17 months, the ORR was 60% and after 35 months it was still close to that at 57.5%. Nearly three-quarters of patients had achieved disease control, meaning stable disease or better. About 30% of patients achieved a CR.
The [mPFS and mOS] were not reached for patients who achieved a CR. Now again, these were not primary end points, so these are just exploratory and nice to look at but also intriguing. The survival was significantly better for the patients who achieved a CR vs the total population and those who achieved only a PR.7
For toxicitiesas you can imagine, because youre using 25 mg of lenalidomideyoure seeing a lot of cytopenia.
Still, not a ton of febrile neutropenia, at just about 12% for grade 3 or 4. There were no grade 5 AEs [adverse events].7
For the nonhematologic AEs, again, youre using lenalidomide, so expect fatigue, diarrhea, a little bit of grade 1 or 2 peripheral edema, decreased appetite, all these things that we know and love from many of our oncology drugs.
Are there any other treatment options to highlight for this patient population?
The new kid on the block is loncastuximab, which is also a CD19-targeted agent, but unlike the [oral] tafasitamab that is FDA approved with the IV lenalidomide, loncastuximab is a single-agent IV drug. Thats one thing its got going for it. Its also an antibody-drug conjugate; in this case, it is a different payload, SG3199. I think this is the first drug approved with this payload, and it has its own AE profile because of this payload.8
The [LOTIS-2 (NCT03589469) is again] a single-arm phase 2 study, but thats what we have and thats what led to the FDA approval of the agent. This study population had 2 or more prior lines of therapy, which is different from the other 2 studies we talked about where they could potentially have had only 1 prior line of therapy. In this case, unlike with the tafasitamab data, if somebody had prior anti-CD19 therapy, they had to have another biopsy to show they were still CD19 positive. If somebody had CAR T-cell therapy and they wanted to get this agent, they had to still be CD19 positive. For the first 2 cycles, the patients got a slightly higher dose of loncastuximab followed by a slightly lower dose. The dosing could continue for up to 3 years.9 For duration of therapy, pola-BR was 6 cycles; tafasitamab plus lenalidomide was 1 year of combination, then ongoing maintenance; and for loncastuximab, it was potentially up to 3 years of treatment but with only a single drug. In this study, the primary end point was ORR, like the tafasitamab plus lenalidomide one.
The ORR was the primary end point and it turned out to be 48%. Median duration of response for the responders was about 10.3 months but was longer if you achieved a CR, so it was out to 13.4 months. They did [subgroup analyses] for some of the high-risk subgroups such as [patients] with transformed disease, or [patients] with double and triple hit and they had good responses. In this study, 15 patients got CAR T-cell therapy after, so loncastuximab was used as a bridge and the ORR to the CAR T-cell therapy was 46.7%. This was a small number, so we cant make too many assessments about it, but you could argue that this is close to what the CAR T-cell ORR is. A few patients also got transplant after loncastuximab.9
REFERENCES:
1. NCCN. Clinical Practice Guidelines in Oncology. B-cell lymphomas, version 5.2021. Accessed November 17, 2021. https://bit.ly/32eVSpA
2. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447
3. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol. 2019;20(1):31-42.doi:10.1016/S1470-2045(18)30864-7
4. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0
5. Sawalha Y, Maddocks K. Profile of polatuzumab vedotin in the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: a brief report on the emerging clinical data.Onco Targets Ther. 2020;13:5123-5133. doi:10.2147/OTT.S219449
6. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165. doi:10.1200/JCO.19.00172
7. Salles G, Duell J, Gonzlez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.Lancet Oncol. 2020;21(7):978-988. doi:10.1016/S1470-2045(20)30225-4
8. Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.Blood. 2018;131(10):1094-1105. doi:10.1182/blood-2017-10-813493
9. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol. 2021;22(6):790-800. doi:10.1016/S1470-2045(21)00139-X
Read the rest here:
Brem Looks at Multiple Treatments for Patients With DLBCL - Targeted Oncology
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
Recent Comments